Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.

PMID:
26679250
2.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

3.

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort.

BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1.

4.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

5.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

6.

Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study).

Rosenthal E, Piroth L, Cua E, Joulié A, Ravaux I, Chauveau M, Lacombe K, Cotte L, Bonnard P, Weiss L, Longuet M, Pradier C, Cacoub P; GERMIVIC Study Group.

AIDS Care. 2014 Feb;26(2):176-85. doi: 10.1080/09540121.2013.803014. Epub 2013 Jun 11.

PMID:
23756091
7.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).

Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12.

8.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.

J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.

9.

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.

Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G; ANRS-112 INTERPRIM Study Group.

AIDS. 2012 Sep 24;26(15):1895-905.

PMID:
22842994
10.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

11.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

12.

X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

Ghosn J, Galimand J, Raymond S, Meyer L, Deveau C, Goujard C, Izopet J, Rouzioux C, Chaix ML; ANRS CO 06 PRIMO cohort.

PLoS One. 2011;6(8):e23301. doi: 10.1371/journal.pone.0023301. Epub 2011 Aug 24.

13.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

14.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.

PMID:
20543702
15.

Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort.

Encrenaz G, Bénard A, Rondeau V, Bonnet F, Lazaro E, Neau D, Dupon M, Dabis F, Mercié P, Chêne G; ANRS CO3 Aquitaine Study Group (Groupe d'Epidémiologie Clinique du Sida en Aquitaine).

Curr HIV Res. 2010 Apr;8(3):212-7.

PMID:
20158455
16.

Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.

Bénard A, Mercié P, Alioum A, Bonnet F, Lazaro E, Dupon M, Neau D, Dabis F, Chêne G; Groupe d'Epidémiologie Clinique du Sida en Aquitaine.

PLoS One. 2010 Jan 26;5(1):e8896. doi: 10.1371/journal.pone.0008896.

17.

Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.

Déti EK, Thiébaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, Pellegrin JL, Malvy D, Tchamgoué S, Dabis F, Morlat P; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

HIV Med. 2010 May;11(5):308-17. doi: 10.1111/j.1468-1293.2009.00780.x. Epub 2009 Dec 9.

18.

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group.

AIDS. 2010 Jan 28;24(3):427-35. doi: 10.1097/QAD.0b013e328334344e.

PMID:
19910787
19.

Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.

Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.

AIDS. 2009 Nov 27;23(18):2485-95. doi: 10.1097/QAD.0b013e3283326879.

PMID:
19898216
20.

Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19).

Hessamfar-Bonarek M, Morlat P, Salmon D, Cacoub P, May T, Bonnet F, Rosenthal E, Costagliola D, Lewden C, Chêne G; Mortalité 2000 & 2005 Study Groups.

Int J Epidemiol. 2010 Feb;39(1):135-46. doi: 10.1093/ije/dyp300. Epub 2009 Oct 5.

PMID:
19805489

Supplemental Content

Loading ...
Support Center